-

Bruker Announces New D6 PHASERTM Benchtop X-Ray Diffraction (XRD) Platform for Materials Analysis and Advanced Research

KARLSRUHE, Germany--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR), the global leader in X-ray diffraction, today announces the new D6 PHASERTM X-Ray Diffraction (XRD) system. The D6 PHASER is a new benchtop XRD platform designed with the analytical flexibility typically only available in larger, floor-standing systems. Unlike conventional, more limited benchtop XRD instruments, the D6 PHASER enables analytical methods that go beyond powder diffraction. With its wide range of capabilities, the D6 PHASER will enable more XRD applications for new markets and user communities.

Building on the success of the D2 PHASER, the D6 PHASER combines the functionality of the floor-standing D8 platform with an innovative benchtop design that includes high X-ray excitation power and a versatile set of X-ray optics. The Motorized Air Scatter Screen (MASS) enables Dynamic Beam Optimization (DBO) for optimum performance over the goniometer range. The D6 PHASER can be equipped with a range of sample stages for a large variety of X-ray diffraction applications, including capillary transmission, grazing incidence diffraction, X-ray reflectometry, residual stress, texture analysis, and non-ambient investigations. The DaVinci stage-interface allows swapping sample stages without realignment.

The patented D6 PHASER goniometer provides intrinsic angular accuracy of 0.01° over the 2θ range. With a touch on the integrated panel, the D6 PHASER automatically performs verification of angular accuracy. The D6 PHASER offers the family of LYNXEYETM detectors. For the analysis of non-perfect powder samples, the user can select the patented Bragg2DTM method. The optional LYNXEYE XE-T detector offers proprietary suppression of Cu-Kß reflections without the usual constraints when using a Kß metal filter.

The versatile D6 PHASER combined with DIFFRAC.SUITETM software provides flexibility for automated push-button methods or to customize measurement configurations for optimized data quality. The D6 PHASER needs no external water cooling and has no special electrical requirements for convenience to bring versatile, high-performance XRD to any laboratory. Finally, the D6 PHASER complies with the latest radiation protection and machinery directives, and it is available as a GxP compliant solution.

Dr. Frank Burgaezy, President of the Bruker AXS Division, commented: “Offering unmatched benchtop capabilities, versatility, and a great user experience, the D6 PHASER is an innovative benchtop X-ray diffraction platform to help users answer today’s materials analysis questions and support tomorrow’s advanced materials discoveries.”

The D6 PHASER makes advanced XRD methods accessible for applied markets like clean energy.

Dr. Jan Vos, Researcher at Magneto Special Anodes stated: “We are heavily invested in the development of electrocatalytic coatings that will form the beating heart of the next generation of water electrolyzers in the green energy transition. Bruker's new D6 PHASER platform will provide us with the extraordinary power, flexibility, and accuracy needed to push our coating development forward. We will have access to advanced X-ray techniques crucial for material science that were previously not available in a compact benchtop system. We are looking forward to creating a big push on the market, and the D6 PHASER will no doubt aid us greatly in making this possible.”

For more information about the D6 PHASER, please visit www.bruker.com/d6phaser.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit www.bruker.com.

Contacts

Media Contact:
Dr. Heiko Ress
Bruker AXS Director Marketing Communications
T: +(49) 721 50997-0
E: heiko.ress@bruker.com

Investor Relations Contact:
Justin Ward
Sr. Director Investor Relations & Corp Development
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Media Contact:
Dr. Heiko Ress
Bruker AXS Director Marketing Communications
T: +(49) 721 50997-0
E: heiko.ress@bruker.com

Investor Relations Contact:
Justin Ward
Sr. Director Investor Relations & Corp Development
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

HANAU, Germany--(BUSINESS WIRE)--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe...

Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

THUN, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of an additional 60% ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker’s ownership to 100%. The transaction adds ultra-fast TOF-MS technology for small-molecule markets, including atmospheric chemistry research, air quality monitoring, exposomics, foods, flavors &a...

Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events...
Back to Newsroom